Inlyta works by inhibiting multiple tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs), which play a critical role in tumor growth and angiogenesis. By blocking these receptors, Inlyta effectively cuts off the blood supply to the tumor, thereby inhibiting its growth and proliferation.
